Figure 1 from Liquid and Tissue Biopsies for Identifying <i>MET</i> Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib
<p>Patient prescreening/screening and enrollment. *One (0.3%) patient was enrolled based on local testing in a protocol violation. LBx-negative, negative for <i>MET</i>ex14 skipping in LBx; LBx-positive, positive for <i>MET</i>ex14 skipping in LBx; LBx<sub>N/A<...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | , , , , , , |
| Publicado em: |
2025
|
| Assuntos: | |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|